“...internationally
recognised thought-leader,
scientific innovator and
entrepreneur in drug
discovery and delivery.”
Globally respected pharmaceutical scientist Dr Ian Wilding has been recognised
with an honorary doctorate from Monash University. The honorary degree of
Doctor of Laws honoris causa, was conferred on Dr Wilding at a ceremony at
the University’s Clayton campus in May.
Dr Wilding, a pharmaceutical drug development
consultant and entrepreneur, was recognised
for his major contributions to international
medicine development, regulatory authorities
and pharmaceutical science organisations in
Europe, Japan and the US.
Professor Bill Charman, Dean of the Faculty of
Pharmacy and Pharmaceutical Sciences and
Director of the Monash Institute of Pharmaceutical
Sciences (MIPS), said Dr Wilding was an
internationally recognised thought-leader,
scientific innovator and entrepreneur in drug
discovery and delivery.
“These advances have had a direct and beneficial
impact on patients across the world through better
design and manufacture of more clinically effective
oral and inhaled medicines,” he noted.
Dr Wilding has published over 250 research
papers, abstracts and patents and shared his
thoughts on the future for pharmaceutical scientists
as guest speaker at the 2015 Emeritus Professor
Barry L. Reed Distinguished Lecture, attracting
a record attendance of over 300 guests.
In 1997 he was appointed as an expert scientist
for the FDA in the area of food effects on drug
bioavailability.
He has also served on several UK and European
Innovation and Enterprise Advisory Boards
including the UK CBI Technology and Innovation
Committee and the European Commission FP7
Advisory Committee for SMEs.
6
In 2005 Dr Wilding received the Controlled Release
Society career achievement award in oral drug
delivery and in 2013 became an Eminent Fellow
of the UK Academy of Pharmaceutical Scientists.
Dr Wilding is also the inventor of the Enterion
capsule, a remote controlled device for site-specific
delivery within the human intestines to evaluate
drug absorption properties that has now been
dosed to several thousand subjects.
In a long career commercialising science,
Dr Wilding was the cofounder of R5
Pharmaceuticals, Zysis, Modern BioSciences
and BioCity Nottingham. In addition to several
Board roles, he currently consults for over 30
pharmaceutical and biotech companies on a wide
range of strategic and technical drug development
issues. He has published over 250 research
papers, abstracts and patents.
Dr Wilding’s honorary doctorate comes just months
after Professor Brian Kobilka MD, a Nobel Prize
winner for chemistry, was similarly recognised for
his research into the pharmacology and biology
of G-Protein-coupled receptors.